---
title: Mystical experiences induced by psychedelic therapies
videoId: rkBq33KWFmY
---

From: [[foundmyfitness]] <br/> 

Dr. Roland Griffiths, a clinical pharmacologist at Johns Hopkins University, has dedicated over 40 years to researching mood-altering drugs and their effects on behavior and brain function <a class="yt-timestamp" data-t="00:00:01">[00:00:01]</a>, <a class="yt-timestamp" data-t="00:01:26">[00:01:26]</a>. His recent work has focused on the profound effects of classic psychedelics, particularly psilocybin, in inducing mystical-type experiences and their potential therapeutic applications <a class="yt-timestamp" data-t="00:01:47">[00:01:47]</a>, <a class="yt-timestamp" data-t="00:02:06">[00:02:06]</a>.

## The Nature of Psilocybin-Induced Mystical Experiences

Dr. Griffiths' interest in these substances began about 20 years ago when his personal [[meditation retreats | meditation practice]] led him to explore altered states of consciousness and personal transformation <a class="yt-timestamp" data-t="00:01:32">[00:01:32]</a>. He became reacquainted with older [[psychedelic_research_and_historical_context | research with classic psychedelics]], which are serotonergically-mediated hallucinogens like LSD, psilocybin, DMT, and mescaline <a class="yt-timestamp" data-t="00:01:47">[00:01:47]</a>, <a class="yt-timestamp" data-t="00:01:54">[00:01:54]</a>.

A study published a decade ago with healthy volunteers demonstrated that psilocybin, when administered under carefully controlled conditions (careful selection, support, and preparation), induces experiences that are "deeply and profoundly personally and spiritually meaningful" <a class="yt-timestamp" data-t="00:02:17">[00:02:17]</a>. These experiences are highly valued by individuals even months after they occur, often being described as among the most significant in their lives, comparable to events like the birth of a firstborn child or the death of a parent <a class="yt-timestamp" data-t="00:02:56">[00:02:56]</a>, <a class="yt-timestamp" data-t="00:03:14">[00:03:14]</a>. Unlike many other mood-altering drugs, people attribute long-term changes in attitudes, moods, and behavior to these experiences <a class="yt-timestamp" data-t="00:04:02">[00:04:02]</a>. They feel they have learned something profoundly important and gained valuable information for moving forward in their lives <a class="yt-timestamp" data-t="00:04:40">[00:04:40]</a>.

### Core Features of Mystical Experiences
The quality of these experiences often maps onto classically reported mystical-type experiences <a class="yt-timestamp" data-t="00:07:11">[00:07:11]</a>. Psychometric measures have well-described their core features <a class="yt-timestamp" data-t="00:07:37">[00:07:37]</a>:
*   **Sense of Unity**: A central feature is the feeling of interconnectedness of all people and things <a class="yt-timestamp" data-t="00:07:53">[00:07:53]</a>.
*   **Sacredness/Reverence**: Accompanied by a sense of sacredness or reverence, feeling humbling <a class="yt-timestamp" data-t="00:08:04">[00:08:04]</a>.
*   **Authenticity/Truth Value**: The experience holds authenticity and truth value, often described as "more real and more true than everyday waking consciousness" <a class="yt-timestamp" data-t="00:08:14">[00:08:14]</a>.
*   **Positive Moods**: Including feelings of love or "heart opening" <a class="yt-timestamp" data-t="00:08:31">[00:08:31]</a>.
*   **Transcendence of Time and Space**: The past and future collapse into the present moment <a class="yt-timestamp" data-t="00:08:37">[00:08:37]</a>.
*   **Ineffability**: Experiences are often described as impossible to put into words <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>.

These features, particularly the sense of unity and truth value, appear to underscore the "reorganizational component" for many individuals <a class="yt-timestamp" data-t="00:09:04">[00:09:04]</a>. People often reflect on these experiences daily, finding them reorganizational to how they perceive themselves and others in the world <a class="yt-timestamp" data-t="00:09:16">[00:09:16]</a>. They can invoke an existential component, prompting reflection on the mystery of consciousness and life's meaning <a class="yt-timestamp" data-t="00:09:35">[00:09:35]</a>, <a class="yt-timestamp" data-t="00:36:06">[00:36:06]</a>.

## Therapeutic Applications and Mechanisms

The profound impact of these experiences led researchers to explore [[potential_therapeutic_applications_of_psilocybin_beyond_cancer_treatment | therapeutic effects]]. One of the first studies investigated psilocybin in [[psilocybin_and_its_effects_on_depression_and_anxiety_in_cancer_patients | cancer patients experiencing significant anxiety or depression]] due to a life-threatening diagnosis <a class="yt-timestamp" data-t="00:11:31">[00:11:31]</a>. Conventional treatments are often limited for this population <a class="yt-timestamp" data-t="00:12:12">[00:12:12]</a>. Studies from Johns Hopkins and NYU showed "striking" and sustained decreases in anxiety and depression after a single psilocybin treatment, with effects lasting up to six months without significant relapse <a class="yt-timestamp" data-t="00:15:03">[00:15:03]</a>, <a class="yt-timestamp" data-t="00:16:15">[00:16:15]</a>.

### Neurobiological Mechanisms
Psilocybin primarily binds to serotonin 5-HT2A and 5-HT2C receptors, with effects largely mediated through 5-HT2A <a class="yt-timestamp" data-t="00:22:48">[00:22:48]</a>, <a class="yt-timestamp" data-t="00:22:52">[00:22:52]</a>. However, the major effects are hypothesized to be downstream and likely glutamate-mediated, linking to [[wholebody_hyperthermia_as_a_treatment_for_depression | ketamine's antidepressant effects]] <a class="yt-timestamp" data-t="00:23:10">[00:23:10]</a>.

A key area of interest is the **default mode network (DMN)**, a brain network active during rumination, self-referential processing, and thinking about the past or future <a class="yt-timestamp" data-t="00:27:08">[00:27:08]</a>, <a class="yt-timestamp" data-t="00:27:51">[00:27:51]</a>. DMN activity is increased in depression <a class="yt-timestamp" data-t="00:27:24">[00:27:24]</a>. Studies show that psilocybin acutely decreases activity within the DMN <a class="yt-timestamp" data-t="00:26:56">[00:26:56]</a>. Interestingly, DMN activity is also decreased in long-term meditators <a class="yt-timestamp" data-t="00:28:24">[00:28:24]</a>, aligning with the goal of meditation to bring one into the present moment and reduce egoic holding <a class="yt-timestamp" data-t="00:28:30">[00:28:30]</a>. This suggests a convergent effect between psilocybin and meditation in altering brain states associated with self-perception and mental rumination <a class="yt-timestamp" data-t="01:02:43">[01:02:43]</a>.

Another potential mechanism is **neurogenesis** (the growth of new brain cells) and **neuroplasticity** (the brain's ability to change connections) <a class="yt-timestamp" data-t="02:10:4">[00:21:04]</a>, <a class="yt-timestamp" data-t="00:36:50">[00:36:50]</a>. Early research in animals suggests psilocybin can increase neurogenesis in areas like the dentate gyrus and cause fear extinction <a class="yt-timestamp" data-t="00:21:04">[00:21:04]</a>, <a class="yt-timestamp" data-t="00:21:12">[00:21:12]</a>. These "reorganizational experiences" induced by psilocybin are thought to involve complex neuroplastic changes <a class="yt-timestamp" data-t="00:37:17">[00:37:17]</a>.

### Broader Therapeutic Potential
Beyond cancer-related distress, psilocybin is being explored for [[potential_therapeutic_applications_of_psilocybin_beyond_cancer_treatment | treatment-resistant depression]] <a class="yt-timestamp" data-t="00:19:07">[00:19:07]</a>, <a class="yt-timestamp" data-t="00:19:29">[00:19:29]</a>. The lasting changes in personality, specifically an increase in "openness," observed after mystical-type experiences are unusual, as personality traits are typically considered stable after the mid-20s <a class="yt-timestamp" data-t="00:38:45">[00:38:45]</a>. This reorganization suggests potential for treating addictions (e.g., smoking cessation, alcoholism, cocaine dependence), PTSD, OCD, and eating disorders <a class="yt-timestamp" data-t="00:39:42">[00:39:42]</a>, <a class="yt-timestamp" data-t="00:40:11">[00:40:11]</a>, <a class="yt-timestamp" data-t="00:41:29">[00:41:29]</a>, <a class="yt-timestamp" data-t="00:42:10">[00:42:10]</a>. The intervention may also be relevant for end-of-life care generally, addressing the existential dimension of meaning for anyone facing mortality <a class="yt-timestamp" data-t="00:43:23">[00:43:23]</a>.

## Controlled Administration and Risks

The administration of psilocybin for therapeutic or research purposes occurs under highly controlled conditions <a class="yt-timestamp" data-t="00:05:22">[00:05:22]</a>. Volunteers undergo extensive preparation, including at least eight hours of rapport-building with facilitators to ensure safety and trust during a high-dose experience <a class="yt-timestamp" data-t="00:05:33">[00:05:33]</a>. During the session, synthesized psilocybin (not mushrooms) is given, and participants lie on a couch with eye shades and headphones, directing their attention inward. Facilitators are present for reassurance and safety, reminding participants that they will return to "consensual reality" <a class="yt-timestamp" data-t="00:05:48">[00:05:48]</a>, <a class="yt-timestamp" data-t="00:06:10">[00:06:10]</a>.

### Importance of Context and Dose
The effects are dose-dependent, with higher doses increasing the probability of both mystical-type and challenging experiences <a class="yt-timestamp" data-t="00:51:49">[00:51:49]</a>, <a class="yt-timestamp" data-t="00:52:36">[00:52:36]</a>. The interaction of context and pharmacology is crucial; these are not simply effects of psilocybin alone <a class="yt-timestamp" data-t="00:44:55">[00:44:55]</a>.

### Potential Risks
While the therapeutic potential is promising, the risks associated with casual psilocybin use should not be minimized <a class="yt-timestamp" data-t="00:45:07">[00:45:07]</a>. These risks contributed to the cultural misunderstanding and removal of psychedelics from clinical research for decades <a class="yt-timestamp" data-t="00:45:19">[00:45:19]</a>. A survey revealed that about 10% of users reported putting themselves or others at risk of physical harm during a "bad trip," and some experienced enduring psychological problems requiring professional help <a class="yt-timestamp" data-t="00:46:12">[00:46:12]</a>. Risks increase when individuals take the compound without knowing the dose, receiving proper support, or having pre-existing vulnerabilities <a class="yt-timestamp" data-t="00:47:01">[00:47:01]</a>. These vulnerabilities include a family history of psychotic or bipolar disorder <a class="yt-timestamp" data-t="00:49:03">[00:49:03]</a>.

Even under controlled conditions, about 30% of volunteers may experience significant fear or anxiety for some duration <a class="yt-timestamp" data-t="00:50:34">[00:50:34]</a>. However, support can help individuals navigate these "difficult experiences," which can sometimes lead to greater insight <a class="yt-timestamp" data-t="00:50:06">[00:50:06]</a>. Predicting who will have a difficult experience remains nearly impossible <a class="yt-timestamp" data-t="00:51:01">[00:51:01]</a>.

## [[Comparative study of different psychedelic substances | Comparison to Other Psychedelics]] and Historical Use

While psilocybin is a serotonergic agonist, other substances like Salvinorin A, a kappa-opioid agonist, induce different types of altered states <a class="yt-timestamp" data-t="01:08:24">[01:08:24]</a>. Salvinorin A is a short-acting hallucinogen, but generally does not induce mystical experiences and can be dysphoric <a class="yt-timestamp" data-t="01:08:52">[01:08:52]</a>, <a class="yt-timestamp" data-t="01:09:13">[01:09:13]</a>. Dimethyltryptamine (DMT), another classic short-acting hallucinogen, is distinct in its phenomenology, though its effects in brews like Ayahuasca (combined with an MAO inhibitor) can be more similar to psilocybin <a class="yt-timestamp" data-t="01:10:33">[01:10:33]</a>.

Indigenous populations globally have used psilocybin mushrooms, Ayahuasca (DMT), and peyote (mescaline) for hundreds or thousands of years <a class="yt-timestamp" data-t="01:11:11">[01:11:11]</a>, <a class="yt-timestamp" data-t="01:12:12">[01:12:12]</a>. Historically, their use is highly controlled within cultural contexts, primarily for religious, healing, or divination purposes, and not casually <a class="yt-timestamp" data-t="01:13:01">[01:13:01]</a>. This suggests that the meaningfulness of these emergent experiences has long been valued within those cultures <a class="yt-timestamp" data-t="01:13:40">[01:13:40]</a>.

The ability to reliably induce these "reorganizational experiences" with psilocybin provides a scientific model for investigating profound human phenomena like mystical experiences, which have historically occurred erratically and unpredictably <a class="yt-timestamp" data-t="00:35:20">[00:35:20]</a>. This opens new avenues for understanding consciousness, personal transformation, and potentially addressing deep existential questions <a class="yt-timestamp" data-t="00:35:37">[00:35:37]</a>.